02 15-06



Express Mail No. EV 687 636 766 US

INFORMATION DISCLOSURE STATEMENT

Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attorney Docket	INTM-018
First Named Inventor	HSU, HENRY H.
Application Number	10/526,087
Confirmation No.	6478
Filing Date	September 14, 2005
Group Art Unit	1646
Examiner Name	

"COMBINATION THERAPY FOR TREATMENT OF Title: FIBROTIC DISORDERS"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. INTM-018 may be charged thereon.

Date: Feb. 13, 2006

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200 East Palo Alto, California 94303 Telephone: (650) 327-3400

Paula A. Borden

Registration No. 42,344

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Facsimile: (650) 327-3231

E 9007 8 1 834 E FEB 13 2

FEB 13 2006

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ired to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number 10/526,087
Filing Date September 14, 2005
First Named Inventor HSU, HENRY H.
Art Unit 1646
Examiner Name To Be Assigned

Sheet 4 Attorney Docket Number INTM-018 **U.S. PATENT DOCUMENTS** Examiner Cite **Document Number Publication Date** Name of Patentee or Pages, Columns, Lines, Where MM-DD-YYYY Applicant of Cited Relevant Passages or Relevant No. Initials' Number-Kind Code² (if known) Document Figures Appear 09-25-2001 US-6,294,350 Peterson US-5.310.562 05-10-1994 Margolin US-5,518,729 05-21-1996 Margolin US-5,716,632 02-10-1998 Margolin US-6,090,822 07-18-2000 Margolin US-5,474,981 12-12-1995 Leder et al. US-5,871,723 12-16-1999 Strieter et al. 03-17-1998 US-5,728,377 Sarris et al. 08-10-1999 US-5,935,567 Leder et al. US-5,994,292 11-30-1999 Tosato et al. US-6,491,906 12-10-2002 Strieter et al. US-5,145,677 09-08-1992 von Eichborn, et al. US-5,362,490 11-08-1994 Kurimoto et al. US-6,153,600 11-28-2000 Leder et al. US-US-US-

		FOREIG	N PATENT DO	CUMENTS		
		Foreign Patent Document			Pages, Columns, Lines, Where Relevant	
Examiner Initials'	Cite No.1	Country Code ³ –Number ⁴ –Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Passages or Relevant Figures Appear	T ⁶
		WO 01/34180	05-17-2001	Lutz-Henning Block		
		EP 795,332	09-17-1997	Lutz-Henning Block		
		WO 01/62274	08-30-2001	Instituto Cientifico Y Tecnologico De Navarra, S.A.		
		WO 99/46392	09-16-1999	The Gov't of the USA represented by The Secretary Department of Health and Human Services		
		EP 0328255		Baker Cummins Pharmaceuticals, inc.		
		W0 01/23006	04-05-2001	Amarillo Biosciences, Inc.		

Examiner	Date		
Signature	Considered	i	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FESS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Papework Reduction Act of 1995 to persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO Application Number 10/526,087 September 14, 2005 Filing Date INFORMATION DISCLOSURE HSU, HENRY H. First Named Inventor STATEMENT BY APPLICANT Art Unit 1646 **Examiner Name** To Be Assigned (use as many sheets as necessary) INTM-018 4 Attorney Docket Number Sheet

FEB 13 2006

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		Ziesche et al. (1999) N. Engl. J. Med. 341:1264-1269	
		du Bois (1999) N. Engl. J. Med. 341:1302-1304	
		King (2000) N. Engl. J. Med. 342:974-975	
		Ziesche and Block (2000) Wien. Klin Wochenschr. 112:785-790;	
		Raghu et al. (1999) Am. J. Respir. Crit. Care Med. 159:1061-1069	
		Stern et al. (2001) Chest 120:213-219;	
		Gay et al. (1998) Am. J. Respir. Crit. Care Med. 157:1063-1072	ļ
		Dayton et al. (1993) Chest 103:69-73	
		Al-Bayati et al. (2002) Biochem. Pharmacol. 64:517-525	-
		Shihab et al. (2002) Am. J. Transplant. 2:111-119	
Examiner		Date	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Reperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 14408/PTO				Complete if Known
Substitute	Substitute for form 1449B/PTO		Application Number	10/526,087	
	INFORMATION DISCL	OSI	IRF	Filing Date	September 14, 2005
	STATEMENT BY APPLICANT			First Named Inventor	HSU, HENRY H.
				Art Unit	1646
	(use as many sheets as necessary)			Examiner Name	To Be Assigned
Sheet 3 of 4				Attorney Docket Number	INTM-018

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Yu et al. (2002) Curr. Opinion Pharmacol. 2:177-181	
		METAVIR (1994) Hepatology 20:15-20	
_		Brunt (2000) Hepatol. 31:241-246	
		Alpini (1997) J. Hepatol. 27:371-380	
		Baroni et al. (1996) <i>Hepatol</i> . 23 :1189-1199	
		Czaja et al. (1989) <i>Hepatol</i> . 10:795-800	
		Grossman et al. (1998) J. Gastroenterol. Hepatol. 13:1058-1060	<u> </u>
		Rockey and Chung (1994) <i>J. Invest. Med.</i> 42:660-670	<u> </u>
		Sakaida et al. (1998) <i>J. Hepatol.</i> 28 :471-479	
······································		Shi et al. (1997) Proc. Natl. Acad. Sci. USA 94:10663-10668	
			L

Examiner	Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act 95, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known				
		Application Number	10/526,087			
INFORMATION DISCLOSURE				Filing Date	September 14, 2005	
STATEMENT BY APPLICANT				First Named Inventor	HSU, HENRY H.	
	OTTAL EMERIT BY THE			Art Unit	1646	
	(use as many sheets as necessary)			Examiner Name	To Be Assigned	
Sheet	4	of	4	Attorney Docket Number	INTM-018	

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹						
		Baroni et al. (1999) <i>Liver</i> 19:212-219					
		Lortat-Jacob et al. (1997) J. Hepatol. 26:894-903					
		Llorent et al. (1996) <i>J. Hepatol.</i> 24:555-563	 				
		Luster and Leder (1996) <i>J. Exp. Med.</i> 178:1057-1065;					
		Tannenbaum et al. (1998) J. Immunol. 161:927-932	_				
		Narvaiza et al. (2000) <i>J. Immunol</i> . 164:3112-3122					
		Du X Weng H Cai W: "Histological changes in 20 hepatic fibrosis patients with chronic hepatitis B after recombinant human interferon gamma treatment" Medline, October 2001					
Examiner Signature	<u> </u>	Date Considered					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.